External
Repatriation Medical Authority Statement

Retinal vascular occlusive disease - Treatment with a drug Factor

Last reviewed for CCPS 05 October 2006.

Investigative Documents

Claimant Report - Nonsteroidal Anti-Inflammatory Drugs (excluding Aspirin) [CR9266]

Medical Report - Treatment with NSAIDs (excluding Aspirin) [MR9345]

Preliminary questions [36282]

36394

there is some evidence that a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, may be a factor in the development of the condition under consideration.

36395 the veteran used a drug as specified in the reasonable hypothesis Statement of Principles before the clinical onset of the condition under consideration.

36396

the veteran's use of a drug as specified in the reasonable hypothesis Statement of Principles was materially contributed to by treatment of an injury or illness which is identifiable.

36751 — the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and VEA service for the clinical onset of retinal vascular occlusive disease.

36397 — the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and operational service for the clinical onset of retinal vascular occlusive disease.

or

36403 — the veteran has established the causal connection between treatment with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs and eligible service for the clinical onset of retinal vascular occlusive disease.

Clinical onset and operational service [36397]

36399 — the identified illness or injury, for which the veteran used a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, is causally related to operational service.

Clinical onset and eligible service [36403]

36752

for treatment of the identified illness or injury, the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs for a period specified in the balance of probabilities Statement of Principles before the clinical onset of the condition under consideration.

36405 — the identified illness or injury, for which the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs, is causally related to eligible service.